Navigation Links
IGI Laboratories Announces Third Quarter 2013 Results

BUENA, N.J., Oct. 29, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the third quarter ended September 30, 2013.


Third Quarter and Year to Date 2013 Highlights

  • Total revenues of $4.0 million in the third quarter of 2013, an increase of 100% over the same quarter in 2012
  • Total revenues of $11.5 million for the nine months ended September 30, 2013, an increase of 84% over the same period in 2012
  • Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and nine months ended September 30, 2013 were $1.4 million, and $4.2 million, respectively
  • Gross profit remained consistent year over year, equaling 31.0% for the nine months ended September 30, 2013 from 31.7% in the same period of 2012
  • IGI filed its eleventh and twelfth Abbreviated Drug Application, or ANDA, with the U.S. Food and Drug Administration (FDA) on July 24, 2013 and September 18, 2013 respectively
  • Net loss was $0.1 million and $1.4 million in the third quarter of 2013 and 2012, respectively
  • Net loss included research and development costs of $0.7 million and $0.6 million in the third quarter of 2013 and 2012, respectively
  • Net loss was $0.8 million and $2.7 million for the nine months ended September 30, 2013 and 2012, respectively
  • IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "Our team has done a tremendous job this quarter.  This quarter marks the fifth consecutive quarter of top line growth.  Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters.  We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013."  Mr. Grenfell-Gardner continued, "Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve.  Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million.  Our team is committed to our plan to file at least six ANDAs in 2013.  We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013."The Company will hold a conference call today at 4:30 pm ET to discuss 3rd quarter 2013 results.

    The Company invites you to listen to the call by dialing 1-877-415-3182. International participants should call 1-857-244-7325. The passcode for the conference call is 58610371.

    This call is being webcast by Thomson and can be accessed at IGI's website at

    The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents (, a password-protected event management site.

     IGI LABORATORIES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share information)(Unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Revenues:Product sales, net

    $  3,950

    $   1,464

    $   11,124

    $   4,835Research and development income




    1,368Licensing, royalty and other income




    52Total revenues




    6,255Cost and expenses:Cost of sales




    4,271Selling, general and administrative expenses




    2,254Product development and research expenses




    1,735Total costs and expenses




    8,260Operating loss




    (2,005)Interest expense and other, net




    (740)Net loss$

    $   (1,422)


    Basic and diluted loss per share$   (0.00)

    $   (0.04)


    (0.07)Weighted Average of Common Stock and Common Stock Equivalents Outstanding  Basic and diluted





    For the nine months ended September 30, 2013 and 2012

    (in thousands)

    (Unaudited)20132012Cash flows from operating activities:Net loss

    (2,745)Non-cash expenses

    6711,388Changes in operating assets and liabilities

    (1,307)156Net cash used in operating activities

    (1,391)(1,201)Cash flows from investing activities:Product acquisition costs

    (1,826)-Capital expenditures

    (223)(323)Net cash used in investing activities

    (2,049)(323)Net cash provided by financing activities

    2,306385Net decrease in cash and cash equivalents

    (1,134)(1,139)Cash and cash equivalents at beginning of period

    2,5362,914Cash and cash equivalents at end of period

    ,775 IGI LABORATORIES, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share information)September 30,
    2013December 31,
    2012*ASSETSCurrent assets:Cash and cash equivalents

    2,536Accounts receivable, net


    2,5231,773Prepaid expenses and other receivables

    232253Total current assets

    7,0526,139Property, plant and equipment, net

    2,6342,691Product acquisition costs, net

    1,796-Restricted cash, long term

    5454License fee, net

    225300Debt issuance costs, net


    155143Total assets

    9,427LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable

    ,091Accrued expenses

    1,079820Deferred income, current

    17948Capital lease obligation, current

    817Total current liabilities

    2,8271,976Note payable, bank

    3,0001,000Deferred income, long term

    620Capital lease obligation, long term

    -4Total liabilities

    5,8333,000Commitments and contingenciesStockholders' equity:Series A Convertible Preferred stock, liquidation preference - $0 and $500,000 at September 30, 2013 and December 31, 2012 



    500Series C Convertible Preferred stock, liquidation preference - $1,822,205 at September 30, 2013 and $1,764,240 at December 31, 2012 


    1,517Common stock457446Additional paid-in capital

    48,38647,409Accumulated deficit

    (44,200)(43,445)Total stockholders' equity

    6,1606,427Total liabilities and stockholders' equity

    9,427* Derived from the audited December 31, 2012 financial statementsAbout IGI Laboratories, Inc.IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

    IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "believe", "target", "estimated," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    SOURCE IGI Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
    2. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
    3. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
    4. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
    5. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
    6. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
    7. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
    8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
    9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
    10. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
    11. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
    Post Your Comments:
    (Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
    (Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
    (Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
    (Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
    (Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
    (Date:10/12/2017)... ... 2017 , ... On Saturday, October 21, the Health & Wellness Center at ... raise money for the American Heart Association Heart Walk. Teams of up to 10 ... to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. ...
    Breaking Medicine News(10 mins):